No Data
No Data
Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.
①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stock concept tracking | Peking expands the scope of medical insurance reimbursement for hematopoietic stem cell transplantation. Stem cell-related pharmaceutical companies benefit (with concept stocks)
Peking Municipal Medical Insurance Bureau: Expanding the scope of medical insurance reimbursement for hematopoietic stem cell transplantation.
Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident That China's High-Level Openness Is a Historical Opportunity
There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings
No Data
No Data